Enoxaparin for thromboprophylaxis after major trauma: Potential cost implications

Critical Care Medicine

Volumn 29, Issue 9, 2001, Pages 1659-1665

  Shorr, Andrew F ^a   Ramage, Anthony S ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Cost; Deep vein thrombosis; Heparin; Low molecular weight heparin; Prophylaxis; Pulmonary embolism; Trauma

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; HEPARIN;

ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; INCIDENCE; INJURY; LUNG EMBOLISM; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

EID: 0034847273     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200109000-00001     Document Type: Article

References (42)

1. Thrombosis risk in the trauma patient: Prevention and treatment
2. A prospective study of venous thromboembolism after major trauma
3. Pulmonary embolism in major trauma patients
4. Deep vein thrombosis and pulmonary embolism in trauma patients
5. Silent deep vein thrombosis in immobilized multiple trauma patients
6. Lethal injuries and time to death in a level I trauma center
7. A clinical trial of venal caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis
8. Venous thromboembolism in trauma patients
9. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail
10. The efficacy of sequential compression devices in multi-trauma patients with severe head injury
11. Efficacy of subcutaneous heparin in the prevention of venous thromboembolic events in trauma patients
12. Low-molecular-weight heparin in the treatment of patients with enous thromboembolism
13. Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism
14. Prevention of venous thromboembolism
15. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
16. Post trauma thromboembolism prophylaxis
17. Recommendations of the panel on cost-effectiveness in health and medicine
18. Low-molecular-weight heparin and heparin induced thrombocytopenia
19. Heparin induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
20. Use of low-molecular-weight heparin in preventing thromboembolism in trauma patients
21. Thromboembolic prophylaxis in orthopedic trauma patients: A comparison between fixed dose and an individually adjusted dose of low-molecular-weight heparin (nadoparin)
22. Distribution of venous thrombi in symptomatic patients
23. The distinction between costs and charges
24. Inferior vena caval filter use in US trauma centers: A practitioner survey
25. Economic analysis of low-dose heparin versus the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colo-rectal surgery
26. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: Outcome of therapy and health economy aspects
27. Deep vein thrombosis prophylaxis in trauma: Cost analysis
28. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma
29. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
30. The journal's policy on cost-effectiveness analyses
31. Low-molecular-weight heparin compared to unfractionated heparin for treatment of acute deep vein thrombosis: A cost effectiveness analysis
32. Long-term cost-effectiveness of low-molecular weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in elective hip replacement
33. Cost-effectiveness of enoxaparin versus low-dose warfarin in prevention of deep-vein thrombosis after total hip replacement surgery
34. Efficacy and cost of low-molecular-weight heparin compared to standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty
35. Subcutaneous low-molecular-weight heparin versus warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation: An economic perspective
36. Cost-effectiveness of anticoagulation prolonged after hospital discharge following general surgery
37. Cost-effectiveness of prevention and treatment of deep vein thrombosis and pulmonary embolism
38. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: Decision and cost-effectiveness analysis
39. Economic evaluation of enoxaparin sodium versus heparin in unstable angina
40. Cost-effectiveness of antiseptic impregnated central venous catheters for the prevention of catheter related blood stream infections
41. Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery
42. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial